Lightnews — Scholar-powered news

The Science of Parkinson's @scienceofpd.bsky.social · 1m

Mission Therapeutics announces it has raised $13.3M to progress the clinical development of their lead candidate MTX325 (a USP30 inhibitor) through a Phase Ib proof-of-mechanism study in patients with #Parkinsons; Due to start in H1 2026
missiontherapeutics.com/mission-ther...

The Science of Parkinson's @scienceofpd.bsky.social · 59m

New review explores evidence supporting the notion that Nicotinamide adenine dinucleotide (NAD+) levels decline with age, as well as the tissue-specific effects of NAD+ precursor supplementation; "extrapolation of rodent-based data is not straightforward"
www.nature.com/articles/s42...

The Science of Parkinson's @scienceofpd.bsky.social · 1h

Over-expression of MitoLbNOX (a mitochondrial-targeted version of the bacterial enzyme LbNOX, which increases regeneration of NAD+ in the mitochondria to maintain the NAD+/NADH ratio) does not protect MCI-Park mice (with impaired mitochondrial complex I)
www.frontiersin.org/journals/cel...

Reposted by The Science of Parkinson's

Heidi M McBride @mitodynamics.bsky.social · 22h

New paper - MAPL strikes again! Interested in mitochondrial signalling, inflammation, lysosome biology, pyroptosis, and Parkinson's disease? Have a look, there's something for everyone! Feeling grateful! @mitocollier.bsky.social Funded by #CIHR, @asapresearch.parkinsonsroadmap.org.
rdcu.be/eKKz1 🇨🇦

3 15 47

The Science of Parkinson's @scienceofpd.bsky.social · 1h

CRISPR screen by @mitodynamics.bsky.social & colleagues identifies Mitochondrial anchored protein ligase (MAPL) as a regulator of gasdermin-mediated release of mtDNA from lysosomes, driving pyroptotic cell death; Depletion of MAPL, LRRK2 or VPS35 blocks cell death
www.nature.com/articles/s41...

The Science of Parkinson's @scienceofpd.bsky.social · 1h

Researchers report that UBQLN2 droplets catalyze α-synuclein fibrillization; UBQLN2 found in substantia nigra Lewy bodies in #Parkinsons cases; Small compound SO286 inhibited both UBQLN2 self-association & interaction with α-syn, suppressing aggregation
www.embopress.org/doi/full/10....

The Science of Parkinson's @scienceofpd.bsky.social · 1h

That's a heck of a response (black arrow; >20 point improvement in UPDRS-III)! Just weeks after transplantation??? In the OFF state???

The Science of Parkinson's @scienceofpd.bsky.social · 1h

12 patients with moderate-to-severe #Parkinsons received bilateral putamen transplantation of low-dose (3.15 million cells; n = 6) or high-dose (6.30 million cells; n = 6) A9-dopamine cells with immunosuppression; 12 months, off-med. MDS-UPDRS part III scores improved

1

The Science of Parkinson's @scienceofpd.bsky.social · 1h

The results of S. Biomedics' open label Phase 1/2a clinical trial of hESC-derived dopamine progenitors in #Parkinsons; Treatment is safe; The rapid response in some patients is baffling, but the DAT-PET imaging looks encouraging
www.cell.com/cell/fulltex...

1

The Science of Parkinson's @scienceofpd.bsky.social · 2d

Looking forward to the @cureparkinsons.org.uk Autumn Research Update meeting; It is FREE (virtual & in-person); Come along & learn what we are funding in #Parkinsons research (big theme for this meeting will be MAMS - multi-arm, multi-stage trial platforms)
cureparkinsons.org.uk/2025/10/autu...

Autumn Research Update Meeting 2025 - Cure Parkinson's

Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10

cureparkinsons.org.uk

1 3

The Science of Parkinson's @scienceofpd.bsky.social · 2d

Researchers present the core clinical features associated with survival in patients with Dementia with Lewy Bodies
www.neurology.org/doi/10.1212/...

Core Clinical Features Associated With Survival in Patients With Dementia With Lewy Bodies | Neurology

Background and ObjectivesThis analysis used clinical data from prospectively followed participants meeting criteria for probable dementia with Lewy bodies (DLB) in the Mayo Clinic Alzheimer's Disease ...

www.neurology.org

The Science of Parkinson's @scienceofpd.bsky.social · 2d

New review article explores targeting metabotropic glutamate receptors for symptomatic & disease-modifying treatment in #Parkinsons
www.nature.com/articles/s41...

The Science of Parkinson's @scienceofpd.bsky.social · 2d

Everything you ever wanted to know about mitochondria-associated membranes - a new review explores molecular organization, cellular functions, & their role in health + disease ( #Parkinsons get a few mentions)
febs.onlinelibrary.wiley.com/doi/10.1002/...

1 2

The Science of Parkinson's @scienceofpd.bsky.social · 2d

Using an unbiased FACS-based genome-wide CRISPR/Cas9 knockout screen, researchers identify key genes & pathways specifically implicated in α-syn PFFs intracellular accumulation, including heparan sulfate proteoglycans biosynthesis & Golgi trafficking
www.nature.com/articles/s42...

1 3

The Science of Parkinson's @scienceofpd.bsky.social · 2d

Researchers present a novel lncRNA FAM151B-DT that regulates degradation of aggregation prone proteins; Silencing FAM151B-DT in vitro is sufficient to enhance tau & #Parkinsons-associated α-synuclein aggregation
www.nature.com/articles/s41...

The Science of Parkinson's @scienceofpd.bsky.social · 2d

The age association aspect of #Parkinsons does not get enough attention.

Now researchers provide a framework to enhance research reproducibility, investigating the nexus of ageing & PD
www.nature.com/articles/s41...

The Science of Parkinson's @scienceofpd.bsky.social · 2d

Interesting: LRRK2 inhibitors for #Alzheimers?

Researchers report LRRK2 deficiency mitigates amyloid β deposition-mediated pathology in a mouse model of AD (by reprogramming microglia)
www.nature.com/articles/s41...

1

The Science of Parkinson's @scienceofpd.bsky.social · 2d

Last week Herantis Pharma presented positive topline data from their Phase 1b trial of small peptide molecule HER-096 (designed to mimic the activity of cerebral dopamine neurotrophic factor; CDNF) in people with #Parkinsons at MDS2025
herantis.com/news-events/...

The Science of Parkinson's @scienceofpd.bsky.social · 2d

The new tube map of London - called the "Expobiome map"

1

The Science of Parkinson's @scienceofpd.bsky.social · 3d

Meta-metabolomics?!?

Ok

If that is what it takes

Researchers identify 11 metabolites that are differentially abundant between #Parkinsons (n=50), prodromal PD (n=30) & control cases (n=50); β-glutamate⬆️in PD and prodromal PD
microbiomejournal.biomedcentral.com/articles/10....

1

The Science of Parkinson's @scienceofpd.bsky.social · 3d

Curiously, dopamine agonist-treated cases of restless leg syndrome (n = 3077) showed a significantly longer restricted mean survival time to #Parkinsons diagnosis, compared to controls

The Science of Parkinson's @scienceofpd.bsky.social · 3d

New retrospective cohort study using Korean National Health Insurance Service data (2002 to 2019) finds restless leg syndrome is associated with an increased risk of developing #Parkinsons; N=9919 patients with RLS & 9919 matched controls
jamanetwork.com/journals/jam...

1

The Science of Parkinson's @scienceofpd.bsky.social · 6d

New research presents a comprehensive genetic catalog of both known & novel coding & splicing variants potentially linked to #Parkinsons etiology in 710 African cases (& 11k controls)
academic.oup.com/brain/advanc...

The Science of Parkinson's @scienceofpd.bsky.social · 6d

Oh look! Speaking of combos

A new funding opportunity to explore rationally designed combination therapies in #Parkinsons

How interesting!
cureparkinsons.org.uk/2025/09/new-...

New funding opportunity: Combination therapies for Parkinson’s - Cure Parkinson's

Cure Parkinson’s is excited to announce that we are now accepting expressions of interest for our new combination therapy funding call. In August, Cure

cureparkinsons.org.uk

3

The Science of Parkinson's @scienceofpd.bsky.social · 6d

Combination therapies! #Alzheimers is doing it, why isn't #Parkinsons?

Human transcriptomic & drug repurposing analyses identify letrozole & irinotecan for AD; Medical records=⬇️lower AD risk in people exposed to letrozole or irinotecan; Combo rescues AD models
www.cell.com/cell/fulltex...

1 1